Ipilimumab inogamuchirwa neChadya neDrug Administration kuti ipe maranoma. Iyi ndiyo nhau dzakanaka kune varwere, avo vainge vaine nguva shoma shoma apo maranoma akapararira kune dzimwe nzvimbo dzomuviri ( danho IV chirwere).
Chii Chinonzi Melanoma?
Chirwere chinonzi melanoma, chinonyanya kukosha chekenza yeganda, chinowedzera mumasero (melanocytes) anogadzira melanin - iyo pigment inopa ganda rako ruvara.
Melanoma inogonawo kuumba mumaziso ako uye, kazhinji, mumitumbi yomukati, yakadai sematumbo ako.
Ipilumumab Inoshanda Sei?
Ipilumumab is an antibody that activates the immune system body to fight melanoma by inhibiting the cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) molecule. CTLA-4 inomukoro paT-cells, rudzi rwechichena chewesero reropa rinotora basa rinokosha pakugadzirisa zvirwere zvekuzvidzivirira zvemuviri. Kuvapo kweCLA-4 kunoderedza zvirwere zvemuviri wezvirwere zvezvirwere zvezvirwere zvezvirwere, saka kudzivirira basa rayo kunogadzirisa maitiro ezvirwere zvekudzivirira zvirwere mumuviri.
Uchapupu Iyo Ipilumumab Inoshanda
Zvitatu chikamu II mishonga yemakirini yakaratidza kuti kurapwa neapilimumab kunobudirira mune rimwe remakore rinoponesa chiyero che 47 kusvika 51 kubva muzana kune vanhu vane danho rechitatu kana IV rinonzi IV, iro rinenge rinopetwa kaviri.
Iko kuri kuedzwa mumatambudziko akareba (chikwata III) pachayo uye pamwe chete nemishonga, zvimwe zvirwere (immleukin-2), uye chemotherapies (zvakadai se dacarbazine).
Zvose zvinotarisana nematambudziko zvinobva kune 13 muzana neapilimumab pamwe nekuvhara muvarwere vane chirwere chechitanhatu IV kusvika ku17 uye 22 muzana neapilimumab pamwe dacarbazine kana interleukin-2, pamwe chete, kune varwere vane chirwere chemasastatic. Mhinduro dzave dzichigara kwenguva refu, uye pakati peavo vane zvirwere zvakanyanya, mizinga yepamusoro yekupindura yakaonekwa (kusvika kusvika 36 muzana).
Izvi zvinoratidza kuti kupfuura chikamu chimwe chete muzvitatu zveralimumab-vakatarirwa nevarwere vane melanoma yakakura vanoona kubatsirwa kwenguva yakareba kubatsirwa, nhau isina kubudirira yenyaya mukurapa chirwere ichi.
Migumisiro Yechiratidzo yePilumumab
Kusiyana nemakemikrasi , mune migumisiro miviri inova pachena nguva pfupi mushure mekutanga kurapwa, migumisiro inobatanidza nelimlimumab inogona kusiyanisa zvikuru, zvichida nokuti masiviri evanhu anowanzosiyana kubva kumunhu kusvika kune munhu.
Zvikamu zvinowanzovhiringidza zvepilimumab zvinowanikwa mumatumbo emimba (zvakadai sezuva uye kurwiswa kwekoloni) uye ganda (zvakadai sokuputika nekuputika kweganda). Pashoma migumisiro inowanzoitika inosanganisira hepatitis, kuvhiringidza kwepituitary gland (hypophysitis), kuora kweziso ( uveitis ), uye zvinetso zvepvo (nephritis). Migumisiro inowanikwa inenge kusvika 84 kubva muzana yevarwere asi inowanzove yakaoma uye inorapwa.
> Sources:
> Hersh E, Weber J, Powderly J, et al (2009). Kugara kwenguva refu kwevarwere (pts) nepamusoro ye melanoma inobatwa neapilimumab kana pasina dacarbazine. J Clin Oncol 27: 15s (suppl; abstr 9038).
> Ledezma B (2009). Ipilimumab yepamusoro ye melanoma: Maonero ekurera. Oncol Nurs Forum, 36 (1), 97-104.
> Mayo Clinic. Kenza Kanzera.
> National Cancer Institute. Ipilimumab
> Sarnaik AA, Weber JS (2009). Kufambira mberi kwekushandisa kushandisa anti-CTLA-4 yekurapa kwechirwere. Cancer J. 2009 May-Jun; 15 (3): 169-73.